Transcriptional profiles of progestogen effects in the postmenopausal breast

Breast Cancer Research and Treatment

Volumn 114, Issue 2, 2009, Pages 233-242

  Wood, Charles E ^a   Register, Thomas C ^a   Cline, J Mark ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen; Hormone therapy; Progesterone; Progestin

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; INITIATION FACTOR 4E BINDING PROTEIN 1; MEDROXYPROGESTERONE ACETATE; MYC PROTEIN; PLACEBO; PROGESTERONE; PROTEIN TYROSINE KINASE; STAT5A PROTEIN; STAT5B PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST; BREAST BIOPSY; CANCER RISK; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE INDUCTION; MACACA; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

ANIMALS; CROSS-OVER STUDIES; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MACACA FASCICULARIS; MAMMARY GLANDS, ANIMAL; MEDROXYPROGESTERONE 17-ACETATE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLACEBOS; POSTMENOPAUSE; PROGESTERONE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TRANSCRIPTION, GENETIC;

EID: 59449093147     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0003-8     Document Type: Article

References (64)

1. The Writing Group for the PEPI Trial 1996 Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 275 370 375
2. MC Pike RK Peters W Cozen 1997 Estrogen-progestin replacement therapy and endometrial cancer J Natl Cancer Inst 89 1110 1116
3. JE Rossouw GL Anderson RL Prentice 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 321 333
4. RT Chlebowski SL Hendrix RD Langer 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial JAMA 289 3243 3253
5. C Schairer J Lubin R Troisi 2000 Estrogen-progestin replacement and risk of breast cancer JAMA 284 691 694
6. RK Ross A Paganini-Hill PC Wan 2000 Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin J Natl Cancer Inst 92 328 332
7. MP Warren 2004 A comparative review of the risks and benefits of hormone replacement therapy regimens Am J Obstet Gynecol 190 1141 1167
8. ML Stefanick GL Anderson KL Margolis 2006 Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy JAMA 295 1647 1657
9. GA Greendale BA Reboussin S Slone 2003 Postmenopausal hormone therapy and change in mammographic density J Natl Cancer Inst 95 30 37
10. GA Greendale BA Reboussin A Sie 1999 Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators Ann Intern Med 130 262 269
11. LJ Hofseth AM Raafat JR Osuch 1999 Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast J Clin Endocrinol Metab 84 4559 4565
12. JM Cline G Söderqvist E von Schoultz 1996 Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques Am J Obstet Gynecol 174 93 100
13. JM Cline G Soderqvist E von Schoultz 1998 Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques Breast Cancer Res Treat 48 221 229
14. JM Cline TC Register TB Clarkson 2002 Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys Menopause 9 422 429
15. GA Colditz 2007 Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin Breast Cancer Res 9 108
16. MM Schapira MA Gilligan TL McAuliffe 2004 Menopausal hormone therapy decisions: insights from a multi-attribute model Patient Educ Couns 52 89 95
17. AL Hersh ML Stefanick RS Stafford 2004 National use of postmenopausal hormone therapy: annual trends and response to recent evidence JAMA 291 47 53
18. M Cirigliano 2007 Bioidentical hormone therapy: a review of the evidence J Womens Health (Larchmt) 16 600 631
19. ML Stefanick 2005 Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration Am J Med 118 Suppl 12B 64 73
20. A Fournier F Berrino E Riboli 2005 Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort Int J Cancer 114 448 454
21. A Fournier F Berrino F Clavel-Chapelon 2008 Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study Breast Cancer Res Treat 107 103 111
22. HR Franke I Vermes 2003 Differential effects of progestogens on breast cancer cell lines Maturitas 46 S55 S58
23. CE Wood TC Register CJ Lees 2007 Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys Breast Cancer Res Treat 101 125 134
24. K Schneider J Oltmanns M Hassauer 2004 Allometric principles for interspecies extrapolation in toxicological risk assessment - empirical investigations Regul Toxicol Pharmacol 39 334 347
25. MAQC Consortium L Shi LH Reid 2006 The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nat Biotechnol 24 1151 1161
26. S Kaiser YK Park JL Franklin 2007 Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer Genome Biol 8 R131
27. RA Irizarry BM Bolstad F Collin 2003 Summaries of Affymetrix GeneChip probe level data Nucleic Acids Res 31 e15
28. CE Wood TC Register AA Franke 2006 Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast Cancer Res 66 1241 1249
29. Y Benjamini Y Hochberg 1995 Controlling the false discovery rate: a practical and powerful approach to multiple testing J Roy Stat Soc B 57 289 300
30. A Reiner D Yekutieli Y Benjamini 2003 Identifying differentially expressed genes using false discovery rate controlling procedures Bioinformatics 19 368 375
31. A Citri Y Yarden 2006 EGF-ERBB signalling: towards the systems level Nat Rev Mol Cell Biol 7 505 516
32. MI Gallego N Binart GW Robinson 2001 Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects Dev Biol 229 163 175
33. KM Quesnelle AL Boehm JR Grandis 2007 STAT-mediated EGFR signaling in cancer J Cell Biochem 102 311 319
34. AP Belsches MD Haskell SJ Parsons 1997 Role of c-Src tyrosine kinase in EGF-induced mitogenesis Front Biosci 2 d501 d518
35. F Rojo L Najera J Lirola 2007 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis Clin Cancer Res 13 81 89
36. F Dif E Saunier B Demeneix 2001 Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor Endocrinology 142 5286 5293
37. E Cocolakis M Dai L Drevet 2008 Smad signaling antagonizes Stat5-mediated gene transcription and mammary epithelial cell differentiation J Biol Chem 283 1293 1307
38. FM Reis S Luisi MM Carneiro 2004 Activin, inhibin and the human breast Mol Cell Endocrinol 225 77 82
39. CF Chang R Westbrook J Ma 2007 Transforming growth factor-beta signaling in breast cancer Front Biosci 12 4393 4401
40. J Lawler 2000 The functions of thrombospondin-1 and-2 Curr Opin Cell Biol 12 634 640
41. DA Spandidos A Pintzas A Kakkanas 1987 Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue Anticancer Res 7 1299 1304
42. SJ Nass RB Dickson 1998 Epidermal growth factor-dependent cell cycle progression is altered in mammary epithelial cells that overexpress c-myc Clin Cancer Res 4 1813 1822
43. CM Li AA Margolin M Salas 2006 PEG10 is a c-MYC target gene in cancer cells Cancer Res 66 665 672
44. HA Coller C Grandori P Tamayo 2000 Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion Proc Natl Acad Sci USA 97 3260 3265
45. JR Pasqualini 2003 Differential effects of progestins on breast tissue enzymes Maturitas 46 S45 S54
46. G Söderqvist M Poutanen M Wickman 1998 17Beta-hydroxysteroid dehydrogenase type 1 in normal breast tissue during the menstrual cycle and hormonal contraception J Clin Endocrinol Metab 83 1190 1193
47. G Carpenter 2000 The EGF receptor: a nexus for trafficking and signaling Bioessays 22 697 707
48. EJ Faivre CA Lange 2007 Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells Mol Cell Biol 27 466 480
49. AR Daniel M Qiu EJ Faivre 2007 Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth Steroids 72 188 201
50. MD Sternlicht 2006 Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis Breast Cancer Res 8 201
51. Y Huang X Li J Jiang 2006 Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells Oncogene 25 7565 7576
52. D Nikolic-Vukosavljevic K Kanjer Z Neskovic-Konstantinovic 2002 Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer Int J Biol Markers 17 196 200
53. MJ Ellis C Ma 2007 Letrozole in the neoadjuvant setting: the P024 trial Breast Cancer Res Treat 105 Suppl 1 33 43
54. RP Ghatge BM Jacobsen SA Schittone 2005 The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells Breast Cancer Res 7 R1036 R1050
55. P Stute CE Wood J Kaplan 2004 Cyclic changes in the mammary gland of cynomolgus macaques Fertil Steril 82 1160 1170
56. B de Lignieres L Dennerstein T Backstrom 1995 Influence of route of administration on progesterone metabolism Maturitas 21 251 257
57. EA Lindenfeld RD Langer 2002 Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial Obstet Gynecol 100 853 863
58. CL Magness PC Fellin MJ Thomas 2005 Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human Genome Biol 6 R60
59. Rhesus Macaque Genome Sequencing and Analysis Consortium, Gibbs RA, Rogers J et al (2007) Evolutionary and biomedical insights from the rhesus macaque genome. Science 316:222-234
60. A Pavlicek VN Noskov N Kouprina 2004 Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition Hum Mol Genet 13 2737 2751
61. G Cheng Y Li Y Omoto 2005 Differential regulation of estrogen receptor (ER) alpha and ERbeta in primate mammary gland J Clin Endocrinol Metab 90 435 444
62. Cline JM, Wood CE (2005-2006) Hormonal effects on the mammary gland of postmenopausal nonhuman primates. Breast Dis 24:59-70
63. CE Wood A Usborne R Tarara 2006 Hyperplastic and neoplastic lesions of the mammary gland in macaques Vet Pathol 43 471 483
64. S Preston-Martin MC Pike RK Ross 1990 Increased cell division as a cause of human cancer Cancer Res 50 7415 7421